Tenax Therapeutics, Inc. (NASDAQ:TENX) [Trend Analysis] moved down reacts as active mover, shares a loss -76.41% to traded at $0.46 and the percentage gap between open changing to regular change was -78.46%. Tenax Therapeutics, Inc. (TENX) reported top-line results from its Phase 3 LEVO-CTS trial. The study did not achieve statistically important reductions in the dual endpoint of death or use of a mechanical assist device at 30 days, nor in the quad endpoint of death, myocardial infarction, need for dialysis, or use of a mechanical assist device at 30 days.
“We are disappointed and surprised by the top-line results from this trial, especially given the promising results from earlier published clinical trials. On the other hand, we are encouraged by the statistically important reduction in incidence of LCOS and use of postoperative secondary inotropes, both of which we believe are clinically important. This is consistent with what we know about how this drug works. In addition, we continue to review the full data set, including the in-process data collection on all-cause mortality through day 90, and will share our complete findings at the upcoming American College of Cardiology (ACC) meeting in March,” said John Kelley, CEO of Tenax Therapeutics.
Finally, analysts shed their light over the TENX price targets; maintaining price high target of 10.50 while at average the price target was 9.25 in contrast with the current price of 0.46. The price targets are usually acts as the boosters or blasters in the performance of stock. A higher price target would definitely provide confidence to investors during the trading action, consideration given by Wall Street Journal.
So does the rankings given by analysts; let us highlight rankings table and we had 2 analysts recommending BUY ratings for current month and for previous month 2 stands on similar situation. For the overall, consensus ratings were for Buy.
CytRx Corporation (NASDAQ:CYTR) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 0.05% to close at $0.41 with the total traded volume of 1.24 Million shares. Fundamentalist can give brighter side of a picture but an analyst can glow the darker parts stored in any investment. Let us view how analysts have ranked CYTR in recent few months. In ratings table the CYTR given BUY ratings by 1 analyst in current phase. As per remarks given by WSJ, overall consensus pool recommends it as Buy security. The firm has institutional ownership of 22.90%, while insider ownership included 2.10%. Its price to sales ratio ended at 241.48. CYTR attains analyst recommendation of 2.50 with week’s performance of 1.15%.